Pharma BD Deal Intelligence
Salix Pharmaceuticals Ltd. / Santarus Inc.
2013 · Acquisition/Merger · $2.6B · Complete
Announcement Sentiment
88
Strongly positive
Salix acquired Santarus at $32/share cash (~$2.6B; 36% premium); expanded Salix's GI portfolio and added primary care/diabetes assets; financed via $800M cash + $1.95B Jefferies committed debt.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Assessment window: 5yr post-close.
Key facts
- Announced Nov 07, 2013
- Closed Jan 02, 2014
- Deal value $2.6B
- Deal type Acquisition/Merger
- Therapeutic area Ulcerative Colitis, Type 2 Diabetes, GERD
- Indications Ulcerative Colitis, Type 2 Diabetes, GERD
- Key assets Uceris (budesonide), Glumetza (metformin ER), Zegerid, Fenoglide
- Mechanism Corticosteroid (Uceris); biguanide (Glumetza); PPI (Zegerid); fenofibrate (Fenoglide)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals